Deoxycytidine

Home
About
Help
History (1)
- Deoxycytidine
- See All Pages

"Deoxycytidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE.

Descriptor ID	D003841
MeSH Number(s)	D03.383.742.680.245.500 D13.570.230.329 D13.570.685.245.500
Concept/Terms	Deoxycytidine Deoxycytidine Cytosine Deoxyribonucleoside Deoxyribonucleoside, Cytosine Cytosine Deoxyriboside Deoxyriboside, Cytosine

Below are MeSH descriptors whose meaning is more general than "Deoxycytidine".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Pyrimidines [D03.383.742]
Pyrimidine Nucleosides [D03.383.742.680]
Cytidine [D03.383.742.680.245]
Deoxycytidine [D03.383.742.680.245.500]
Nucleic Acids, Nucleotides, and Nucleosides [D13]
Nucleosides [D13.570]
Deoxyribonucleosides [D13.570.230]
Deoxycytidine [D13.570.230.329]
Pyrimidine Nucleosides [D13.570.685]
Cytidine [D13.570.685.245]
Deoxycytidine [D13.570.685.245.500]

Below are MeSH descriptors whose meaning is related to "Deoxycytidine".

Below are MeSH descriptors whose meaning is more specific than "Deoxycytidine".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Deoxycytidine" by people in this website by year, and whether "Deoxycytidine" was a major or minor topic of these publications.

Bar chart showing 28 publications over 15 distinct years, with a maximum of 4 publications in 2013 and 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	0	1	1
2005	0	2	2
2006	1	1	2
2007	0	1	1
2008	0	1	1
2010	2	1	3
2011	0	1	1
2013	3	1	4
2015	1	1	2
2016	0	3	3
2017	2	2	4
2018	1	0	1
2019	0	1	1
2020	1	0	1
2023	0	1	1

Below are the most recent publications written about "Deoxycytidine" by people in Profiles.

Sayin S, Rosener B, Li CG, Ho B, Ponomarova O, Ward DV, Walhout AJM, Mitchell A. Evolved bacterial resistance to the chemotherapy gemcitabine modulates its efficacy in co-cultured cancer cells. Elife. 2023 02 03; 12.

View in: PubMed
Philip PA, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Manzano Mozo JL, Kim EJ, Dowden S, Zakari A, Borg C, Terrebonne E, Rivera F, Sastre J, Bathini V, L?pez-Trabada D, Asselah J, Saif MW, Shiansong Li J, Ong TJ, Nydam T, Hammel P. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol. 2020 03; 5(3):285-294.

View in: PubMed
Marchand B, Pitarresi JR, Reichert M, Suzuki K, Laczk? D, Rustgi AK. PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells. Oncogene. 2019 05; 38(22):4325-4339.

View in: PubMed
Barbour M, Bujold KE, Tjarks BJ, Jassim AD. A Case of Small Cell Lung Carcinoma in a 15-Year-Old Boy and Literature Review. J Pediatr Hematol Oncol. 2018 10; 40(7):563-566.

View in: PubMed
Weiss GJ, Blaydorn L, Beck J, Bornemann-Kolatzki K, Urnovitz H, Sch?tz E, Khemka V. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Invest New Drugs. 2018 02; 36(1):96-102.

View in: PubMed
Weiss GJ, Waypa J, Blaydorn L, Coats J, McGahey K, Sangal A, Niu J, Lynch CA, Farley JH, Khemka V. A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). Br J Cancer. 2017 Jun 27; 117(1):33-40.

View in: PubMed
Hemming ML, Wagner AJ, Nucci MR, Chiang S, Wang L, Hensley ML, George S. YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy. Gynecol Oncol. 2017 06; 145(3):531-535.

View in: PubMed
Gilzad-Kohan H, Sani S, Boroujerdi M. Calcitriol Reverses Induced Expression of Efflux Proteins and Potentiates Cytotoxic Activity of Gemcitabine in Capan-2 Pancreatic Cancer Cells. J Pharm Pharm Sci. 2017; 20(0):295-304.

View in: PubMed
Muralidharan-Chari V, Kohan HG, Asimakopoulos AG, Sudha T, Sell S, Kannan K, Boroujerdi M, Davis PJ, Mousa SA. Microvesicle removal of anticancer drugs contributes to drug resistance in human pancreatic cancer cells. Oncotarget. 2016 Aug 02; 7(31):50365-50379.

View in: PubMed
Rajeshkumar NV, Yabuuchi S, Pai SG, Tong Z, Hou S, Bateman S, Pierce DW, Heise C, Von Hoff DD, Maitra A, Hidalgo M. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. Br J Cancer. 2016 08 09; 115(4):442-53.

View in: PubMed

People

Explore

Similar Concepts

Top Journals